EP0941336A2 - Papillomavirus, agents pour les depister et pour traiter des maladies causees par ces virus - Google Patents
Papillomavirus, agents pour les depister et pour traiter des maladies causees par ces virusInfo
- Publication number
- EP0941336A2 EP0941336A2 EP97949918A EP97949918A EP0941336A2 EP 0941336 A2 EP0941336 A2 EP 0941336A2 EP 97949918 A EP97949918 A EP 97949918A EP 97949918 A EP97949918 A EP 97949918A EP 0941336 A2 EP0941336 A2 EP 0941336A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- papillomavirus
- protein
- virus
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001631646 Papillomaviridae Species 0.000 title claims abstract description 67
- 201000010099 disease Diseases 0.000 title claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 5
- 241000700605 Viruses Species 0.000 title description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 8
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 238000002255 vaccination Methods 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 238000010367 cloning Methods 0.000 claims description 9
- 238000001574 biopsy Methods 0.000 claims description 6
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 claims description 5
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 92
- 239000013612 plasmid Substances 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710157639 Minor capsid protein Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710136297 Protein VP2 Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007169 ligase reaction Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101710112324 Glutathione S-transferase L1 Proteins 0.000 description 1
- 241001446459 Heia Species 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne un ADN de codage d'un peptide de la protéine qui forme la capside principale d'un papillomavirus ou de codage d'un génome de papillomavirus. L'invention concerne également les protéines codées par le génome de papillomavirus et les anticorps qui s'attaquent à ces protéines, ainsi que leur utilisation en diagnostic, en thérapie et en vaccination.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19648962A DE19648962C1 (de) | 1996-11-26 | 1996-11-26 | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| DE19648962 | 1996-11-26 | ||
| PCT/DE1997/002659 WO1998023752A2 (fr) | 1996-11-26 | 1997-11-12 | Papillomavirus, agents pour les depister et pour traiter des maladies causees par ces virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0941336A2 true EP0941336A2 (fr) | 1999-09-15 |
Family
ID=7812821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97949918A Ceased EP0941336A2 (fr) | 1996-11-26 | 1997-11-12 | Papillomavirus, agents pour les depister et pour traiter des maladies causees par ces virus |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6413522B1 (fr) |
| EP (1) | EP0941336A2 (fr) |
| JP (1) | JP2001505767A (fr) |
| DE (1) | DE19648962C1 (fr) |
| WO (1) | WO1998023752A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19712541C1 (de) * | 1997-03-25 | 1998-11-05 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| DE19735118C1 (de) | 1997-08-13 | 1998-08-13 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| WO2005036456A2 (fr) * | 2003-05-12 | 2005-04-21 | Princeton University | Procede et dispositif pour la segmentation de premier plan de sequences video |
| AU2011258501B2 (en) | 2010-05-25 | 2016-07-07 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4415743C2 (de) * | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| DE19526386C1 (de) * | 1995-07-19 | 1997-01-02 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
-
1996
- 1996-11-26 DE DE19648962A patent/DE19648962C1/de not_active Expired - Fee Related
-
1997
- 1997-11-12 US US09/319,056 patent/US6413522B1/en not_active Expired - Fee Related
- 1997-11-12 WO PCT/DE1997/002659 patent/WO1998023752A2/fr not_active Application Discontinuation
- 1997-11-12 JP JP52412698A patent/JP2001505767A/ja active Pending
- 1997-11-12 EP EP97949918A patent/EP0941336A2/fr not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9823752A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998023752A3 (fr) | 1998-07-16 |
| WO1998023752A2 (fr) | 1998-06-04 |
| US6413522B1 (en) | 2002-07-02 |
| JP2001505767A (ja) | 2001-05-08 |
| DE19648962C1 (de) | 1998-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0809700B1 (fr) | Particules semblables au virus du papillome, proteines de fusion et leur procede de production | |
| DE69531308T2 (de) | Verfahren zur Herstellung von gereinigten papillomavirus Proteinen | |
| DE4415743C2 (de) | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen | |
| DE19526386C1 (de) | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen | |
| DE69933875T2 (de) | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. | |
| DE19648962C1 (de) | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen | |
| DE19735118C1 (de) | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen | |
| DE19712541C1 (de) | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen | |
| DE19840263C1 (de) | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen | |
| WO2004029631A2 (fr) | Procede pour identifier des proteines, specifiques de la barriere hemato-encephalique (bhe), et des fragments de ces dernieres | |
| EP0354440A1 (fr) | Papillomavirus humain type 57, son ADN, et protéines encodées par cette dernière | |
| DE3722968A1 (de) | Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine | |
| WO1996041887A1 (fr) | Proteine a activite de desoxyribonuclease | |
| DE19816186A1 (de) | GDNF-kodierende DNA, Teile davon und GDNF-Varianten | |
| EP0904384A2 (fr) | Proteine apparentee a la tyrosine-phosphatase | |
| EP1015583A2 (fr) | Proteine contenant un domaine srcr | |
| DE19649606C1 (de) | Systeme zur Bestimmung von Wirksubstanzen gegen HPV-assoziierte Karzinome | |
| DE19730997C1 (de) | SRCR Domäne-enthaltendes Protein | |
| EP0449170A1 (fr) | Protéine d'attachement cellulaire ayant une affinité pour la région régulatrice du papilloma virus humain de type 18 | |
| DE19905883C2 (de) | Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV | |
| DE19518488C1 (de) | Autoantigen, geeignet zur Feststellung einer Thromboseneigung | |
| WO2002055542A2 (fr) | Peptides specifiques du virus du papillome humain (hpv) qui bloquent la liaison entre ledit virus et la cellule hote | |
| WO2000022117A1 (fr) | Proteine tumorale | |
| DE19520421A1 (de) | Autoantigen, geeignet zur Feststellung einer Thromboseneigung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990623 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
| 17Q | First examination report despatched |
Effective date: 20011220 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20040215 |